Nyrada Inc. (NYR.AX)
AUD 0.12
(-4.17%)
AUD 0.12
(-4.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.38 Million AUD | 82.26% |
| 2023 | -7.81 Million AUD | -96.72% |
| 2022 | -3.97 Million AUD | -12.68% |
| 2021 | -3.52 Million AUD | 38.93% |
| 2020 | -5.77 Million AUD | -41.0% |
| 2019 | -4.09 Million AUD | -69.47% |
| 2018 | -2.41 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -1.52 Million AUD | 0.0% |
| 2024 FY | -1.38 Million AUD | 82.26% |
| 2024 Q2 | 135.29 Thousand AUD | 0.0% |
| 2023 FY | -7.81 Million AUD | -96.72% |
| 2023 Q2 | -2.67 Million AUD | 0.0% |
| 2023 Q4 | -5.15 Million AUD | 0.0% |
| 2022 Q4 | -1.16 Million AUD | 0.0% |
| 2022 FY | -3.97 Million AUD | -12.68% |
| 2022 Q2 | -2.81 Million AUD | 0.0% |
| 2021 Q4 | -854.53 Thousand AUD | 0.0% |
| 2021 FY | -3.52 Million AUD | 38.93% |
| 2021 Q2 | -2.68 Million AUD | 0.0% |
| 2020 FY | -5.77 Million AUD | -41.0% |
| 2020 Q4 | -3.39 Million AUD | 0.0% |
| 2020 Q2 | -2.3 Million AUD | 0.0% |
| 2019 Q2 | -2.57 Million AUD | -100.0% |
| 2019 Q4 | -1.52 Million AUD | 0.0% |
| 2019 FY | -4.09 Million AUD | -69.47% |
| 2019 Q1 | -1.28 Million AUD | 0.0% |
| 2018 FY | -2.41 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | 74.24% |
| Biome Australia Limited | -1.67 Million AUD | 17.002% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 97.109% |
| Biotron Limited | -3.43 Million AUD | 59.662% |
| Acrux Limited | -5.8 Million AUD | 76.1% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 92.751% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 90.005% |
| BTC Health Limited | 1.05 Million AUD | 231.36% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 88.937% |
| CSL Limited | 2.64 Billion AUD | 100.052% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 96.725% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 103.89% |
| Immutep Limited | -39.89 Million AUD | 96.525% |
| Memphasys Limited | -4.44 Million AUD | 68.793% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 100.882% |
| Noxopharm Limited | -3.57 Million AUD | 61.258% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 83.173% |
| Race Oncology Limited | -13.81 Million AUD | 89.969% |
| Starpharma Holdings Limited | -8.16 Million AUD | 83.022% |
| Tissue Repair Ltd | -4.13 Million AUD | 66.501% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 119.904% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 4.48% |
| Bio-Gene Technology Limited | -2.4 Million AUD | 42.461% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 96.209% |
| Patrys Limited | -3.53 Million AUD | 60.832% |
| Orthocell Limited | -7.18 Million AUD | 80.696% |
| Imugene Limited | -149.68 Million AUD | 99.074% |
| PYC Therapeutics Limited | -37.72 Million AUD | 96.325% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | 78.259% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 85.775% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 84.15% |
| Nanollose Limited | -1.15 Million AUD | -19.858% |
| Invex Therapeutics Ltd | -1.64 Million AUD | 15.567% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 527.571% |
| Amplia Therapeutics Limited | -4.5 Million AUD | 69.219% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | 51.604% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 126.602% |
| Dimerix Limited | -17.07 Million AUD | 91.882% |
| PharmAust Limited | -9.03 Million AUD | 84.653% |
| Hexima Limited | -933.87 Thousand AUD | -48.438% |
| AnteoTech Limited | -8.88 Million AUD | 84.39% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 97.637% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 92.151% |
| Avecho Biotechnology Limited | -3.43 Million AUD | 59.662% |
| Actinogen Medical Limited | -13.04 Million AUD | 89.373% |
| Immuron Limited | -6.93 Million AUD | 80.017% |
| Argenica Therapeutics Limited | -5.47 Million AUD | 74.702% |